Vesalius Therapeutics is a Cambridge, Massachusetts biotech founded by Flagship Pioneering that aims to reconceptualize how common diseases are understood and treated. Its premise: illnesses that drive roughly 90% of human disease burden are not single conditions but constellations of genetically and biologically distinct diseases. Vesalius uses AI, human genetics and genomics, and patient-derived iPSC cell models to spot hidden clinical patterns, trace them to causal gene circuits, and discover novel drug targets for conditions like Parkinson's, heart failure, type 2 diabetes, and Alzheimer's.
Mirador Therapeutics is a San Diego precision-medicine company building first- and best-in-class therapies for immune-mediated inflammatory and fibrotic diseases. Its Mirador360 engine fuses human genetics, multi-modal patient data, AI and advanced analytics to find novel targets, design combination therapies and identify the patients most likely to respond. Founded in 2024 by the former Prometheus Biosciences leadership team, Mirador launched with more than $400 million and has since raised over $650 million total.